HVO Hvivo Plc

TIDMVENN

RNS Number : 8156B

Venn Life Sciences Holdings PLC

09 October 2015

Venn Life Sciences Holdings plc

("Venn" or the "Company"

Result of General Meeting and Update on Acquisition

The Board of Venn Life Sciences Holdings plc (AIM: VENN), a growing Clinical Research Organisation providing clinical trial management solutions and resourcing solutions to pharmaceutical, biotechnology and medical device clients, announces that at its General Meeting held earlier today, 9 October 2015, all resolutions were duly passed.

The Placing Shares are expected to be admitted to trading on AIM on Monday 12 October 2015. The acquisition of Kinesis Pharma BV is scheduled to complete on Friday 16 October 2015 and the Consideration Shares are expected to be admitted to trading on Monday 19 October 2015.

For further information:

 
 Venn Life Sciences Holdings Plc                        www.vennlifesciences.com 
 Tony Richardson, Chief Executive                           Tel: +353 154 99 341 
  Officer 
 Jonathan Hartshorn, Chief Financial 
  Officer 
 Orla McGuinness, Marketing Manager                    Tel: +33 (0)1 30 82 67 07 
 
 Zeus Capital (Nominated Adviser 
  and Co-Broker) 
 Andrew Jones/Phil Walker                                     Tel: 0161 831 1512 
 Dominic Wilson/Alex Davies                                   Tel: 020 3829 5000 
 
 Hybridan LLP (Co-Broker) 
 Claire Louise Noyce                                          Tel: 020 3764 2341 
 
 Walbrook PR Ltd                       Tel: 020 7933 8787 or venn@walbrookpr.com 
 Paul McManus                                                 Mob: 07980 541 893 
 Lianne Cawthorne                                             Mob: 07584 391 303 
 

About Venn Life Sciences:

Venn Life Sciences is a Clinical Research Organisation providing clinical trial management and resourcing solutions to pharmaceutical, biotechnology and medical device organisations. With dedicated operations in France, Germany, the Netherlands, the UK, Ireland and Europe wide representation - Venn specialises in rapid deployment and management of multisite projects. Venn also has an innovation division - Innovenn - focused primarily on breakthrough development opportunities in Skin Science.

This information is provided by RNS

The company news service from the London Stock Exchange

END

MSCFMMGGGLNGKZM

(END) Dow Jones Newswires

October 09, 2015 06:38 ET (10:38 GMT)

Hvivo (LSE:HVO)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024

Hvivo (LSE:HVO)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024